Business Wire

JSSI Accelerates Digital Strategy With TRAXXALL Acquisition

Share

Jet Support Services, Inc. (JSSI), the leading independent provider of maintenance support and financial services to the business aviation industry, today announced the acquisition of TRAXXALL. Founded in 2013, TRAXXALL provides software-as-a-service (“SaaS”) solutions for aircraft maintenance tracking, parts inventory management, and cloud-based software to enhance aircraft maintenance, repair and overhaul (MRO) workflow. Headquartered in Montreal, Canada, TRAXXALL has offices around the world.

TRAXXALL has quickly emerged as a significant player in the maintenance tracking market. Named by the Financial Times as one of the Americas’ fastest growing companies, TRAXXALL delivers software to help customers reduce aircraft downtime, improve data accuracy, and have comprehensive visibility over maintenance costs, parts inventory, and MRO operations.

“JSSI and TRAXXALL have a shared history of challenging the status quo and putting customers first,” said Neil Book, CEO of JSSI. “This business combination presents an exciting opportunity to deliver huge value to our customers and dramatically accelerate the growth trajectory for both companies.”

TRAXXALL’s global team will join JSSI’s growing SaaS division, which comprises previous acquisition SierraTrax, reporting to Ash Reddy, recently promoted to the position of chief operating officer at JSSI.

“We take great pride in our reputation in the business aviation market as a thought partner and maintenance advisor to a robust and diverse fleet of aircraft around the world,” said Reddy. “As we now combine TRAXXALL with JSSI’s core products and data, we are confident in our ongoing business mission to add tangible value for aircraft owners, operators, and maintenance facilities.”

“I am so incredibly proud of what the Traxxall team has achieved,” said Scott Henderson, CEO of TRAXXALL. “I could not think of a better long-term partner for our business than the team at JSSI.”

“JSSI’s values are firmly aligned with our own and will allow us to further develop and enhance our suite of products,” added Mark Steinbeck, president of TRAXXALL. “With direct access to JSSI’s data and capabilities, we will rapidly grow the maintenance tracking business alongside the SierraTrax brand and deliver advanced maintenance tracking solutions to a wider cross section of the business aviation community.”

In addition to its growing maintenance tracking software business, JSSI provides aircraft parts, engines and APUs to hundreds of operators across all makes and models through its JSSI Parts & Leasing business and offers a range of digital tools through Conklin & de Decker to help customers benchmark and compare aircraft ownership options with the most accurate performance and comparison data available. This move to develop the company’s maintenance tracking offering further establishes JSSI as the go-to source for business aviation intelligence and support for the entire aircraft life cycle.

GTCR, a leading private equity firm, is a majority investor in JSSI.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Chiara Lawrance
clawrance@8020comms.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release

Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t

Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye